anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A process for producing an artificial ocular epithelium is disclosed comprising culturing corneal stem cells (e.g. limbal corneal epithelial stem cells) or compositions comprising such cells on a plastically-compacted collagen gel substrate under conditions which provide a population of corneal epithelial cells which produce an artificial ocular epithelium on the substrate. Artificial ocular tissue comprising artificial ocular epithelium and plastically-compacted collagen gel substrate obtained by said process is also claimed. The plastically-compacted collagen gel may be produced from collagen gel by applying a compressing force, dehydration, and/or stretching the gel. The artificial ocular epithelium produced by this method may be used for in vitro ocular toxicity testing, corneal transplantation or methods of treating ocular injury. An artificial ocular epithelium comprising a continuous stratified epithelium of 3-7 cell layers, which expresses cytokeratin-3(CK3) and cytokeratin-14 (CK14), and which has basal membrane components within and between the basal cells, is also claimed.
The utility model relates to a facial mask and gauze mask, eyepiece and face guard that have facial mask, facial mask include base member and glue solution layer, and it has a centre hole to open at least in the middle of the base member, and the base member side is equipped with flexible composite bed, and flexible composite bed establishes to form sealing connection with gauze mask, eyepiece or face guard looks adaptation shape, and the periphery of gauze mask, eyepiece or face guard forms sealing connection through the facial mask when wearing. The mask comprises a mask body and a mask, wherein the mask is arranged on the periphery of the mask body. The eyepiece includes eyepiece body and facial mask, and eyepiece body periphery is equipped with the facial mask. The mask comprises a mask body and a facial mask, wherein the facial mask is arranged on the periphery of the mask body. The utility model discloses need not to change the structure and the fixed band tensile force of current gauze mask, eyepiece or face guard, can improve the sealed effect when gauze mask, eyepiece, face guard use. The utility model discloses not only use comfortablely, can moisten people's face skin through the facial mask glue solution moreover. Is particularly suitable for medical masks, dust masks, diving goggles, fire masks, gas masks and the like.
PURPOSE:To obtain a new compound useful as a medicine for improving cerebral function, an anticataract agent or a cosmetic material. CONSTITUTION:A compound of formula I [R1 and R2 are each H or methyl; R3 is an alpha-amino acid, an omega-amino acid or a peptide bonded at its N-terminal, provided that it represents a bond to thiol group in cysteine or glutathione which contains respectively a thioll or its salt, e.g. 1-(sulfoethylamino)-3-(alpha- tocopheryl-6-yloxy)propan-2-ol. The compound of formula I can be synthesized by reacting a compound of formula II with an alpha-amino acid, an omega-amino acid or a peptide in the presence of an alkali (e.g. potassium hydroxide) preferably in a solvent (e.g. dioxane-alcohol) under heating. In the case R3 in the compound of formula I is glutamic acid, aspartic acid or glutathione, its alkaline salt exhibits a high water solubility and a moisture retention property and is useful as an ultraviolet-absorbing component of a cosmetic, a whitening component and a stabilization component for other cosmetics.
Objective methods for diagnosing or detecting cancer, or determining a predisposition to developing cancer is described herein. In one embodiment, the present invention provides a diagnostic method that utilizes the expression level of LRRC42 as an index of cancer. The present invention further provides methods of screening for therapeutic substances useful in the treatment of LRRC42-associated disease, such as cancer, e.g. lung cancer. The invention further provides methods of inhibiting the cell growth and thus treating or alleviating one or more symptoms of LRRC42-associated diseases. The invention also features double-stranded molecules that inhibit the expression of LRRC42 gene, vectors encoding thereof and compositions containing them.
Delirium is a common clinical syndrome characterized by acute cognitive dysfunction with core features of inattention, disorganized thinking, perceptual disturbances and sleep-wake cycle disruption. It is typically multifactorial and can be triggered by acute infection, metabolic derangements, surgery, and certain medications. Older adults have a much higher incidence of delirium. Delirium increases in-hospital mortality, length of stay, rate of institutionalization and may cause or exacerbate cognitive impairment. The present pilot study investigates sleep loss as potentially important contributing factors in delirium and an opportunity for intervention. Sleep disruption is prevalent among hospitalized patients. Sufficient sleep is important for recovery from illness, management of pain, wound healing, and a variety of other biologic functions integral to recovery in addition to its putative role in delirium prevention. Melatonin plays an important role in circadian rhythms and sleep-wake cycle regulation. Melatonin secretion is altered in hospitalized older patients in comparison with community-living older individuals. Melatonin and the melatonin-receptor agonist Ramelteon have been studied and have shown promise in delirium prevention, in addition to promoting sleep. We propose to test the use of Ramelteon to decrease delirium and improve sleep/wake cycles in the elderly surgical patients.
Participants in this condition will receive 3 days of text messages for 4 weeks. Day 1 will consist of psychoeducation about CBT skill, day 2 will be a remainder to use the skill that is framed with toward future benefits from doing so, and day 3 will have a simple reminder to use the skill.
Capsules of atorvastatin. Daily dose of 80 mg for max. 10 years or until development of castration resistance.
*Please refer to the amoxicillin and clarithromycin full prescribing information, Contraindications and Warnings and Precautions sections, and for information regarding dosing in elderly and renally-impaired patients.   
†Controlled studies did not extend beyond indicated duration.   
‡For patients who do not heal with lansoprazole delayed- release capsules for eight weeks (5 to 10%), it may be helpful to give an additional eight weeks of treatment. If there is a recurrence of erosive esophagitis, an additional eight week course of lansoprazole delayed- release capsules may be considered.   
§Varies with individual patient. Recommended adult starting dose is 60 mg once daily. Doses should be adjusted to individual patient needs and should continue for as long as clinically indicated. Dosages up to 90 mg twice daily have been administered. Daily dose of greater than 120 mg should be administered in divided doses. Some patients with Zollinger-Ellison syndrome have been treated continuously with lansoprazole for more than four years.   
¶ Controlled studies did not extend beyond 12 months.
Alopecia areata (AA), depression, anxiety, and decreased quality of life are highly associated in the literature. It has been noted that there is an increased risk of substance use in those with AA to help cope with the psychological burdens and perceived stigmatization. This study aims to explore the relationship between substance use disorder (SUD) and scarring/non-scarring alopecia using the All of Us database. Of the 9,385 patients with alopecia, 8.4% had SUD of any kind. Multivariable regression revealed that alopecia is a potential protective factor against SUD when controlling for other covariates of significance, with a decreased odds of 0.73. Substance use disorder prevalence was not different between scarring and non-scarring alopecia. This may be the result of patients fearing exacerbation of hair loss, or due to increased mental health and community support in patients with alopecia. Dermatologists and primary care providers should continue to promote psychotherapy and community support to patients whose diagnosis of alopecia has a negative psychosocial impact.
Methods for treating ST-segment elevation myocardial infarction in a human patient 75 years of age or older. The methods comprise administering a dose of less than 1 mg per kg body weight, about .75 mg per kg of body weight, or .75 mg per kg of body weight of enoxaparin sodium by subcutaneous injection approximately every twelve hours for a therapeutic dosing period. The methods may include fibrinolytic therapy. The treatment methods may be used to prevent one or more of, mortality, myocardial re-infarction, myocardial ischemia, stroke, or severe congestive heart failure. Articles of manufacture for use in connection with treating ST-segment elevation myocardial infarction in a human patient 75 years of age or older are also disclosed. The articles of manufacture comprise enoxaparin sodium, and instructions designed to achieve administration to a patient of a dose of less than 1 mg per kg body weight, about .75 mg per kg of body weight, or .75 mg per kg of body weight of enoxaparin sodium, by subcutaneous injection approximately every twelve hours for a therapeutic dosing period.
PROBLEM TO BE SOLVED: To obtain a hair growing agent having a higher hair growing efficacy than that of the conventionally known hair growing agent by blending the extracted material of a specific crude drug with Minoxidil showing a hair growing efficacy albeit insufficient. SOLUTION: This hair growing agent is obtained by using Minoxidil together with the extracted material of Magnolia officinalis (also, M. obovata and M. var. biloba). It is preferable that the blending amount of Minoxidil is 0.1-2wt.% and that of the extracted essence of the Magnolia officinalis is 0.01-5wt.%. Minoxidil is a compound having a chemical name of 6-(1-piperidinyl)-2, 4- pyrimidinediamine-3-oxide and its medically acceptable salts. The extracted material of the Magnolia officinalis is obtained by cutting the bark of the Magnolia officinalis to a suitable size, preferably drying, crushing, then immersing the crushed bark into a water soluble solvent at a room temperature or under heating, sufficiently extracting and then filtering insoluble materials off.  To use this hair growing agent for treatment or prevention of male-type dspilations, it is used as a usual preparation for external use such as a lotion and a tonic preparation.
Indocyanine Green for injection USP is a sterile, lyophilized green powder containing 25 mg of indocyanine green with no more than 5% sodium iodide. It is packaged with Sterile Water for injection, USP used to dissolve the indocyanine green. Indocyanine Green for injection USP is to be administered intravenously. 

Indocyanine green is a water soluble, tricarbocyanine dye with a peak spectral absorption at 800 nm. The chemical name for Indocyanine Green is 1 H-Benz[e]indolium, 2-[7-[1,3-dihydro-1,1-dimethyl-3-(4-sulfobutyl)-2H-benz[e] indol-2-ylidene]-1,3,5-heptatrienyl]-1,1-dimethyl-3-(4-sulfobutyl)-,hydroxide, inner salt, sodium salt. Indocyanine Green for injection USP has a pH of approximately 6.5 when reconstituted. Each vial of Indocyanine Green for injection USP contains 25 mg of indocyanine green as a sterile lyophilized powder.
The patients will receive iron isomaltoside 1000 (Monofer®) as an i.v. infusion of 1000 mg (diluted with normal saline, 10 mg/ml) twice; 3 days before surgery and 3 days after surgery. They will receive iron isomaltoside 1000 (Monofer®) 1000 mg over 15 min.
BACKGROUND & AIMS: Men are more prone to develop and die from liver fibrosis than women. In this study, we aim to investigate how sex-determining region Y gene (SRY) in hepatocytes promotes liver fibrosis.
METHODS: Hepatocyte-specific Sry knock-in (KI), Sry knockout (KO), and Sry KI with platelet-derived growth factor receptor α (Pdgfrα) KO mice were generated. Liver fibrosis was induced in mice by bile duct ligation for 2 weeks or carbon tetrachloride treatment for 6 weeks. In addition, primary hepatocytes, hepatic stellate cells (HSCs), and immortalized cell lines were used for in vitro studies and mechanistic investigation.
RESULTS: Compared to females, the severity of toxin- or cholestasis-induced liver fibrosis is similarly increased in castrated and uncastrated male mice. Among all Y chromosome-encoded genes, SRY was the most significantly upregulated and consistently increased gene in fibrotic/cirrhotic livers in male patients and in mouse models. Sry KI mice developed exacerbated liver fibrosis, whereas Sry KO mice had alleviated liver fibrosis, compared to age- and sex-matched control mice after bile duct ligation or administration of carbon tetrachloride. Mechanistically, both our in vivo and in vitro studies illustrated that SRY in hepatocytes can transcriptionally regulate Pdgfrα expression, and promote HMGB1 (high mobility group box 1) release and subsequent HSC activation. Pdgfrα KO or treatment with the SRY inhibitor DAX1 in Sry KI mice abolished SRY-induced HMGB1 secretion and liver fibrosis.
CONCLUSIONS: SRY is a strong pro-fibrotic factor and accounts for the sex disparity observed in liver fibrosis, suggesting its critical role as a potentially sex-specific therapeutic target for prevention and treatment of the disease.
IMPACT AND IMPLICATION: We identified that a male-specific gene, sex-determining region Y gene (SRY), is a strong pro-fibrotic gene that accounts for the sex disparity observed in liver fibrosis. As such, SRY might be an appropriate target for surveillance and treatment of liver fibrosis in a sex-specific manner. Additionally, SRY might be a key player in the sexual dimorphism observed in hepatic pathophysiology more generally.
PURPOSE: A pharmaceutical composition for treating allergic rhinitis is provided to obtain an oriental medicinal extract which is effectively applied to a preventive and therapeutic agent for allergic rhinitis. CONSTITUTION: A pharmaceutical composition for treating allergic rhinitis contains extracts containing 2-10g of Amydae Carapax, 4-10g of Lonicerae flos, 4-10g of Cryptotympana pustulata, 4-10g of Stellaria dichotoma L. var. lanceolata Bge., 4-10g of Ledebouriella seseloides WOLFF., 4-10g of Schisandra chinensis, 4-10g of Magnolia denudata, 4-10g of Xanthium strumarium, 4-10g of Angelica dahurica roots, 4-10g of Torilis japonica (Houtt.) DC., 4-10g of Sophora flavescens Solander ex Aiton, 4-10g of Scutellariae radix, 4-10g of Lonicera japonica Thunberg, 4-10g of Schizonepeta tenuifolia var. japonica, 4-10g of Ulmus davidiana var. japonica bark, 4-10g of Luffae fructus retininervus, 4-10g of peppermint, and 4-10g of Tribulus terrestris L. as active ingredients. A method for manufacturing the pharmaceutical composition comprises: a step of dipping an oriental medicinal material mixture and extracting by ultrasonic wave at 60 deg. C for 2 hours to prepare a primary extract; a step of filtering the primary extract and concentrating; and a step of extracting the concentrate with purified water. [Reference numerals] (AA) Equivalent mix; (BB) Individual mix; (CC) Mix and hot water extract
Provided herein are compositions and methods of using a Mu opioid receptor (MOR) antagonist (e.g. axelopran) alone or in combination with checkpoint inhibitor (such as e.g. an inhibitor of the PD-1/PD-L1 pathway (e.g. an antibody such e.g. pembrolizumab)) and/or an inhibitor of VEGF (e.g. bevacizumab) for reducing angiogenesis or treating cancer. Also provided herein are kits containing a MOR antagonist (e.g. axelopran) alone or in combination with checkpoint inhibitor and/or an inhibitor of VEGF for reducing angiogenesis or treating cancer.
BACKGROUND: Maternal morbidity and mortality is rising in the United States. Previous studies focus on patient attributes, and most of the national data are based on research performed at urban tertiary care centers. Although it is well understood that nurses affect patient outcomes, there is scant evidence to understand the nurse work system, and no studies have specifically studied rural nurses. The authors sought to understand the systems-level factors affecting rural obstetric nurses when their patients experience clinical deterioration.
METHODS: The research team used a qualitative descriptive approach, including a modified critical incident technique, in interviews with bedside nurses (n = 7) and physicians (n = 4) to understand what happens when patients experience clinical deterioration. Physicians were included to better understand the systems in which nurses work. Clinicians were interviewed at three rural hospitals in New England, with a mean births per year of 190.
FINDINGS: Six systems-level factors/themes were identified: (1) shortages of resources; (2) need for teamwork; (3) physicians' multiple conflicting and simultaneous responsibilities, such as seeing patients in the office while women labor on the hospital floor; (4) need for all team members to be at the top of their game; (5) process issues during high-acuity patient transfer, including difficulty finding available beds at tertiary care centers; and (6) insufficient policies that take low-resource contexts into account, such as requiring two registered nurses to remove emergency medications from the medication cabinet.
CONCLUSION: Rural nurses need policies and protocols that are written with their hospital context in mind. Hospitals may need outside support for content expertise, but policies should be co-created with clinicians with rural practice experience.
OBJECTIVES: Whipple's disease (WD) results from infection of the bacteria Tropheryma whipplei (TW). This disease is characterized by macrophage infiltration of intestinal mucosa and primarily affects Caucasian males. Genetic studies of host susceptibility are scarce. Nucleotide-binding oligomerization domain containing protein 2 (NOD2) is an innate immune sensor, resides mainly in monocytes/macrophages and contributes to defence against infection and inflammatory regulation. NOD2 mutations are associated with autoinflammatory diseases. We report the association of NOD2 mutations with TW and WD for the first time.
METHODS: A multicentre, retrospective study of three patients with WD was conducted. Patients received extensive multidisciplinary evaluations and were cared for by the authors. NOD2 and its association with infection and inflammation were schematically represented.
RESULTS: All patients were Caucasian men and presented with years of autoinflammatory phenotypes, including recurrent fever, rash, inflammatory arthritis, gastrointestinal symptoms and elevated inflammatory markers. All patients underwent molecular testing using a gene panel for periodic fever syndromes and were identified to carry NOD2 mutations associated with NOD2-associated autoinflammatory disease. Despite initially negative gastrointestinal evaluations, repeat endoscopy with duodenal tissue biopsy ultimately confirmed WD. After initial ceftriaxone and maintenance with doxycycline and/or HCQ, symptoms were largely controlled, though mild relapses occurred in follow-up.
CONCLUSION: Both NOD2 and TW/WD are intensively involved in monocytes/macrophages. WD is regarded as a macrophage disease. NOD2 leucin-rich repeat-associated mutations in monocytes/macrophages cause functional impairment of these cells and consequently may make the host susceptible for TW infection and WD, especially in the setting of immunosuppression.
Group 3 will consist of 10 subjects without evidence of inflammatory systemic or inflammatory central nervous system disease, who require CSF removal for some other cause, such treatment of benign intracranial hypertension or as part of the procedure for insertion of an intrathecal medication delivery system. Patients will have a blood draw to provide serum and a CSF will be obtained through a lumbar puncture.
Provided is a technology that easily performs display control in accordance with the location at which a portable terminal is positioned. This embodiment of a medical information display system has a storage unit, a medical information acquisition unit, an identification unit, and a display control unit. The storage unit stores the result of associating rooms in a hospital with medical information processing applications that display medical information or processing results at a display device in the hospital. The medical information acquisition unit acquires medical information displayed at the display device. The identification unit identifies the room at which the portable terminal is positioned. The display control unit executes the medical information processing application associated with the room identified by the identification unit, and medical information or processing results are displayed at the display device by means of executing the medical information processing application.
This study will examine the utility of plasma and urinary based biomarkers for the anxiolytic properties of kava, a natural dietary supplement. The investigators will conduct a one week, double blind, randomized placebo controlled trial of kava, dosed at three 75 mg capsules per day, vs placebo, in adults with generalized anxiety disorder. Clinical measures of anxiety, blood, and urine will be obtained. Biomarkers of interest include PRKACA, cortisol, urinary TCE, and NA5HT. Participants will be assessed pre- and post-treatment. The participants will also be followed for 12 weeks after the end of treatment to identify any potential rare adverse events, particularly liver toxicity, that appear in a delayed fashion.
BACKGROUND: Essential thrombocythemia (ET) is a myeloproliferative neoplasm characterized by uninhibited platelet production. It can present with vasomotor symptoms, and less commonly, severe thrombotic events such as myocardial infarction. ST-segment elevation myocardial infarction (STEMI) secondary to the hypercoagulable state in ET is a diagnostic challenge as the complication is rare, especially outside the typical demographics affected by ET such as the female and elderly populations.
CASE PRESENTATION: Here we report a case of a 32-year-old male found to have STEMI and a markedly elevated platelet count. Angiography revealed occlusion of the left anterior descending and left circumflex arteries, requiring percutaneous intervention and Impella support. The patient was later diagnosed with essential thrombocythemia, treated with hydroxyurea and antiplatelet therapy, and discharged with a wearable cardioverter defibrillator.
CONCLUSIONS: This case illustrates the potential for severe thrombotic complications such as STEMI due to ET. Severe thrombotic complications are less common manifestations of ET in general, particularly in young males. Recognition and diagnosis of ET are critical for the institution of appropriate therapy and prevention of STEMI and cardiogenic shock among other complications.
PURPOSE:To provide a cosmetic stick containing ascorbyl magnesium phosphate, stable to heat and having excellent applicability. CONSTITUTION:The objective cosmetic stick contains a solid oil component and a liquid oil component and is compounded with 1-6wt.% of L-ascorbyl magnesium phosphate (APM). The addition of APM increases the melting temperature without increasing the ratio of the solid oil component and gives a cosmetic stick having excellent applicability. Furthermore, the solid oil content can be decreased and the feeling can be improved without lowering the melting temperature of the cosmetic stick. The addition of the compound is effective in decreasing the formation of defective product caused by the melting of base of cosmetics (e.g. lipstick, stick foundation, cream, beauty wash, eyebrow pencil, temporary hair-dye and pencil-type cosmetic) in summer season.